Details for Patent: 9,326,945

Which drugs does patent 9,326,945 protect, and when does it expire?

Patent 9,326,945 protects ELIQUIS and is included in one NDA.

This patent has ninety-six patent family members in twenty-nine countries.

Summary for Patent: 9,326,945

Title:	Apixaban formulations
Abstract:	Compositions comprising crystalline apixaban particles having a D.sub.90 equal to or less than 89 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
Inventor(s):	Patel; Jatin (West Windsor, NJ), Frost; Charles (Yardley, PA), Jia; Jingpin (Belle Mead, NJ), Vemavarapu; Chandra (Hillsborough, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ) Pfizer Inc. (New York, NY)
Application Number:	13/579,796
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,326,945
Patent Claim Types: see list of patent claims	Composition; Formulation; Dosage form;

Drugs Protected by US Patent 9,326,945

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-001	Dec 28, 2012	AB	RX	Yes	No			Y
Bristol Myers Squibb	ELIQUIS	apixaban	TABLET;ORAL	202155-002	Dec 28, 2012	AB	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,326,945

PCT Information
PCT Filed	February 24, 2011	PCT Application Number:	PCT/US2011/025994
PCT Publication Date:	September 01, 2011	PCT Publication Number:	WO2011/106478

International Family Members for US Patent 9,326,945

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011220775
Brazil	112012021337
Canada	2791171
China	102770126